Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. is rated 'Strong Buy' by MarketsMOJO, with this rating last updated on 08 Apr 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 01 May 2026, providing investors with the latest insights into its performance and outlook.

Surging to a fresh 52-week and all-time high of Rs 2471.05 on 29 Jun 2026, Glenmark Pharmaceuticals Ltd. has demonstrated remarkable price momentum, outpacing its sector and the broader market with a 77.00% gain over the past year. This rally is underpinned by a confluence of bullish technical indicators and sustained upward price action across multiple timeframes.

Extending its winning streak to three sessions, Glenmark Pharmaceuticals Ltd. surged to a fresh all-time high of Rs 2,471.05 on 29 Apr 2026, outperforming the broader Sensex by 1.26 percentage points. This milestone caps a remarkable run where the stock has gained 6.57% over the past three days amid heightened volatility and strong technical signals.

Surging to an all-time high of Rs 2,374 on 28 Apr 2026, Glenmark Pharmaceuticals Ltd. has demonstrated remarkable price momentum, outpacing its sector and the broader market with a 68.75% gain over the past year. This milestone reflects a confluence of strong technical signals and sustained upward price action that has captured investor attention.

Glenmark Pharmaceuticals Ltd. has reached a significant milestone by touching its all-time high price on 28 April 2026, reflecting a robust performance across multiple financial and technical parameters. This achievement underscores the company’s sustained growth and strong market positioning within the Pharmaceuticals & Biotechnology sector.

Glenmark Pharmaceuticals Ltd. has witnessed a significant 19.5% surge in open interest in its derivatives segment, signalling heightened market activity and evolving positioning among traders. Despite a modest price decline of 1.14% on 24 Apr 2026, the stock remains buoyant above key moving averages, reflecting a complex interplay between bullish sentiment and short-term profit-taking.

Glenmark Pharmaceuticals Ltd. has witnessed a notable 17.23% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest price decline of 1.39% on 24 Apr 2026, the surge in open interest and volume suggests evolving directional bets amid a backdrop of strong technical indicators and sector-aligned performance.

Glenmark Pharmaceuticals Ltd. has witnessed a notable 15% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a slight dip in the stock price, the pharmaceutical mid-cap continues to demonstrate robust underlying strength, supported by rising volumes and sustained investor interest.

Glenmark Pharmaceuticals Ltd. has witnessed a notable 12.36% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest decline in the stock price, the surge in open interest alongside rising volumes suggests evolving directional bets within the Pharmaceuticals & Biotechnology sector.

Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a slight dip in the stock price, the pharmaceutical company’s futures and options market data reveal increased participation and potential directional bets, underscoring evolving sentiment in the Pharmaceuticals & Biotechnology sector.

Surging to a fresh 52-week and all-time high of Rs 2,371.6 on 24 Apr 2026, Glenmark Pharmaceuticals Ltd. has demonstrated remarkable price momentum, outpacing its sector and the broader market despite a weakening Sensex. This milestone caps a sustained rally that has seen the stock appreciate over 63% in the past year, underscored by a confluence of bullish technical indicators and robust fundamental metrics.

Glenmark Pharmaceuticals Ltd. has reached a significant milestone, hitting an all-time high price of Rs. 2,370.5 on 24 April 2026. This achievement reflects the company’s robust performance across multiple financial and technical parameters, underscoring its strong position within the Pharmaceuticals & Biotechnology sector.

Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and potential directional bets. The stock recently hit a new 52-week and all-time high of Rs 2,359.4, supported by robust volume and positive price action, reflecting growing investor confidence in the mid-cap pharmaceutical player.

Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and potential directional bets. The stock recently hit a new 52-week and all-time high of ₹2,359.4, supported by robust volume and positive price action, reflecting growing investor confidence in the mid-cap pharmaceutical player.

Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and potential directional bets. The stock’s recent price action, coupled with increased volumes and a strong Mojo Score upgrade, suggests growing investor confidence in the mid-cap pharmaceutical player.

Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and potential directional bets. The stock recently hit a new 52-week and all-time high of Rs 2,359.4, supported by strong volume and positive price action, reflecting growing investor confidence in the mid-cap pharmaceutical player.

Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and bullish positioning. The stock recently hit a new 52-week and all-time high of Rs 2,359.4, supported by strong volume and positive price action, reflecting growing investor confidence in the mid-cap pharmaceutical player.